Publications by authors named "C Lanni"

Background/objectives: Amyloid peptides, whose accumulation in the brain as senile plaques is associated with the onset of Alzheimer's disease, are also found in cerebral vessels and in circulation. In the bloodstream, amyloid peptides promote platelet adhesion, activation, oxidative stress, and thrombosis, contributing to the cardiovascular complications observed in Alzheimer's disease patients. Natural compounds, such as curcumin, are known to modulate platelet activation induced by the hemostatic stimuli thrombin and convulxin.

View Article and Find Full Text PDF

Objective: The aim of the study was to characterize drug prescription patterns in elderly patients hospitalized in acute wards as a function of cognitive status and staff training.

Methods: We recorded clinical parameters reflecting health status and drug prescriptions at admission, during hospital stay, and at discharge before and after a short staff training on the needs of aged cognitively impaired patients. Participants aged 65 and older had a Mini-Mental State Examination (MMSE) score ≥16.

View Article and Find Full Text PDF

Oxidative stress and neuroinflammation play a pivotal role in triggering the neurodegenerative pathological cascades which characterize neurodegenerative disorders, such as Alzheimer's and Parkinson's diseases. In search for potential efficient treatments for these pathologies, that are still considered unmet medical needs, we started from the promising properties of the antidiabetic drug pioglitazone, which has been repositioned as an MAO-B inhibitor, characterized by promising neuroprotective properties. Herein, with the aim to broaden its neuroprotective profile, we tried to enrich pioglitazone with direct and indirect antioxidant properties by hanging polyphenolic and electrophilic features that are able to trigger Nrf2 pathway and the resulting cytoprotective genes' transcription, as well as serve as radical scavengers.

View Article and Find Full Text PDF
Article Synopsis
  • Recent clinical trials show that monoclonal antibodies targeting Aβ have only modest effectiveness in treating conditions related to Alzheimer's disease (AD), indicating that more research is needed to fully understand Aβ's role in the disease's progression.
  • Despite some drugs like aducanumab and lecanemab being approved, uncertainties remain regarding their safety and efficacy, prompting both academic and pharmaceutical efforts to explore new treatment options.
  • The review emphasizes the importance of understanding the complete biological context of Aβ, as it shifts from a normal function to a harmful one, suggesting that successful AD treatment will require addressing multiple related processes beyond just targeting Aβ or neuroinflammation.
View Article and Find Full Text PDF

Catechols have been largely investigated as antiaggregating agents toward β-amyloid peptide. Herein, as a follow up of a previous series of hydroxycinnamic derivatives, we synthesized a small set of dihydroxy isomers for exploring the role of the reciprocal position of the two hydroxyl functions at a molecular level. - and -derivatives effectively reduced amyloid fibrillization, while the -analogue was devoid of any activity in this respect.

View Article and Find Full Text PDF